ImmunityBio Shares Surge 42% After EU Grants Conditional Approval for Anktiva Bladder Cancer Therapy
Feb 18, 2026
ImmunityBio's stock jumped 41.9% following the European Commission's conditional marketing authorization for Anktiva combined with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer across 33 European countries.